Saxagliptin: A novel antiparkinsonian approach

Neuropharmacology

Volumn 89, Issue , 2015, Pages 308-317

  Nassar, Noha N ^a   Al Shorbagy, Muhammad Y ^a   Arab, Hany H ^a   Abdallah, Dalaal M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Apoptosis; BDNF; Dipeptidyl peptidase 4; Dopamine; Free radical; Parkinson disease; Rotenone cAMP; Saxagliptin

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CYCLIC AMP; CYTOCHROME C; DIPEPTIDYL PEPTIDASE IV; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SAXAGLIPTIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; ADAMANTANE; ANTIPARKINSON AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE I; INSECTICIDE; NERVE PROTEIN; NFE2L2 PROTEIN, RAT;

ADULT; AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPARKINSONIAN ACTIVITY; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; ENERGY METABOLISM; IMMUNOREACTIVITY; MOTOR COORDINATION; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; RAT MODEL; SUBSTANTIA NIGRA PARS COMPACTA; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BODY WEIGHT; BRAIN; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; LIPID PEROXIDATION; MALE; METABOLISM; WISTAR RAT;

ADAMANTANE; ANIMALS; ANTIPARKINSON AGENTS; BODY WEIGHT; BRAIN; CATHEPSIN C; CYCLIC AMP; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; INSECTICIDES; LIPID PEROXIDATION; MALE; NERVE TISSUE PROTEINS; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE; RATS; RATS, WISTAR; ROTENONE; TYROSINE 3-MONOOXYGENASE;

EID: 84908344678     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.10.007     Document Type: Article

References (70)

1. H.M. Abd El-Gawad, D.M. Abdallah, and H.S. El-Abhar Rotenone-induced parkinson's like disease: modulating role of coenzyme Q10 J. Biol. Sci. 4 2004 568 574
2. S.J. Allen, and D. Dawbarn Clinical relevance of the neurotrophins and their receptors Clin. Sci. (Lond) 110 2006 175 191
3. E. Alvarez, M.D. Martinez, I. Roncero, J.A. Chowen, B. Garcia-Cuartero, J.D. Gispert, C. Sanz, P. Vazquez, A. Maldonado, C.J. de, M. Desco, M.A. Pozo, and E. Blazquez The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem J. Neurochem. 92 2005 798 806
4. S. Ansorge, K. Nordhoff, U. Bank, A. Heimburg, H. Julius, D. Breyer, A. Thielitz, D. Reinhold, and M. Tager Novel aspects of cellular action of dipeptidyl peptidase IV/CD26 Biol. Chem. 392 2011 153 168
5. A.R. Aroor, S. McKarns, V.G. Demarco, G. Jia, and J.R. Sowers Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance Metabolism 62 2013 1543 1552
6. P. Barneoud, M. Mazadier, J.M. Miquet, S. Parmentier, P. Dubedat, A. Doble, and A. Boireau Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat Neuroscience 74 1996 971 983
7. S.B. Berman, and T.G. Hastings Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease J. Neurochem. 73 1999 1127 1137
8. G. Bertilsson, C. Patrone, O. Zachrisson, A. Andersson, K. Dannaeus, J. Heidrich, J. Kortesmaa, A. Mercer, E. Nielsen, H. Ronnholm, and L. Wikstrom Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J. Neurosci. Res. 86 2008 326 338
9. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
10. T. Carlsson, C. Winkler, M. Lundblad, M.A. Cenci, A. Bjorklund, and D. Kirik Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia Neurobiol. Dis. 21 2006 657 668
11. C.Y. Chang, M.J. Song, S.B. Jeon, H.J. Yoon, D.K. Lee, I.H. Kim, K. Suk, D.K. Choi, and E.J. Park Dual functionality of myeloperoxidase in rotenone-exposed brain-resident immune cells Am. J. Pathol. 179 2011 964 979
12. B.S. Choi, K. Sapkota, S. Kim, H.J. Lee, H.S. Choi, and S.J. Kim Antioxidant activity and protective effects of Tripterygium regelii extract on hydrogen peroxide-induced injury in human dopaminergic cells, SH-SY5Y Neurochem. Res. 35 2010 1269 1280
13. C.A. Colton, and D.L. Gilbert Production of superoxide anions by a CNS macrophage, the microglia FEBS Lett. 223 1987 284 288
14. M. Crompton Mitochondrial intermembrane junctional complexes and their role in cell death J. Physiol. 529 Pt 1 2000 11 21
15. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
16. S. Ekins, J. Mestres, and B. Testa In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling Br. J. Pharmacol. 152 2007 9 20
17. D.F. Fitzsimmons, T.C. Moloney, and E. Dowd Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism Behav. Brain Res. 169 2006 352 355
18. G. Gardian, and L. Vecsei Medical treatment of Parkinson's disease: today and the future Int. J. Clin. Pharmacol. Ther. 48 2010 633 642
19. G.S. Georgy, N.N. Nassar, H.A. Mansour, and D.M. Abdallah Cerebrolysin Ameloriates cognitive deficits in type III diabetic rats PLoS One 8 2013 e64847
20. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 9 2003 589 595
21. M.D. Gorrell Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders Clin. Sci. (Lond) 108 2005 277 292
22. R. Haobam, K.M. Sindhu, G. Chandra, and K.P. Mohanakumar Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains Behav. Brain Res. 163 2005 159 167
23. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J. Neuroinflamm. 5 2008 19
24. K. Hunter, and C. Holscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci. 13 2012 33
25. ILAR Guide for the Care and Use of Laboratory Animals 1996 National Academy Press Washington, D.C
26. T. Iwasa, T. Matsuzaki, R. Kinouchi, G. Gereltsetseg, M. Murakami, M. Munkhzaya, T. Altankhuu, A. Kuwahara, T. Yasui, and M. Irahara Changes in central and peripheral inflammatory responses to lipopolysaccharide in ovariectomized female rats Cytokine 65 2014 65 73
27. D.S. Kania, J.D. Gonzalvo, and Z.A. Weber Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus Clin. Ther. 33 2011 1005 1022
28. A.J. Kastin, V. Akerstrom, and W. Pan Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier J. Mol. Neurosci. 18 2002 7 14
29. D. Katagiri, Y. Hamasaki, K. Doi, K. Okamoto, K. Negishi, M. Nangaku, and E. Noiri Protection of glucagon-like Peptide-1 in Cisplatin-induced renal injury elucidates Gut-kidney connection J. Am. Soc. Nephrol. 24 12 2013 2034 2043 10.1681/ASN.2013020134
30. P.M. Keeney, J. Xie, R.A. Capaldi, and J.P. Bennett Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled J. Neurosci. 26 2006 5256 5264
31. N. Khurana, M.P. Ishar, A. Gajbhiye, and R.K. Goel PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice Eur. J. Pharmacol. 662 2011 22 30
32. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J. Endocrinol. 202 2009 431 439
33. M. Kitazawa, J.R. Wagner, M.L. Kirby, V. Anantharam, and A.G. Kanthasamy Oxidative stress and mitochondrial-mediated apoptosis in dopaminergic cells exposed to methylcyclopentadienyl manganese tricarbonyl J. Pharmacol. Exp. Ther. 302 2002 26 35
34. L.L. Kong, Z.Y. Wang, N. Han, X.M. Zhuang, Z.Z. Wang, H. Li, and N.H. Chen Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats J. Neuroinflamm. 11 2014 112
35. J. Kosaraju, C.C. Gali, R.B. Khatwal, A. Dubala, S. Chinni, R.M. Holsinger, V.S. Madhunapantula, S.K. Muthureddy Nataraj, and D. Basavan Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease Neuropharmacology 72 2013 291 300
36. A. Lagunin, A. Stepanchikova, D. Filimonov, and V. Poroikov PASS: prediction of activity spectra for biologically active substances Bioinformatics 16 2000 747 748
37. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J. Biol. Chem. 278 2003 471 478
38. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, K. Sambamurti, A. Brossi, D.K. Lahiri, M.P. Mattson, B.J. Hoffer, Y. Wang, and N.H. Greig GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc. Natl. Acad. Sci. U. S. A. 106 2009 1285 1290
39. B. Liu Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease AAPS J. 8 2006 E606 E621
40. W.J. Liu, H.Y. Jin, K.A. Lee, S.H. Xie, H.S. Baek, and T.S. Park Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats Br. J. Pharmacol. 164 2011 1410 1420
41. S. Love, P. Plaha, N.K. Patel, G.R. Hotton, D.J. Brooks, and S.S. Gill Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain Nat. Med. 11 2005 703 704
42. E.L. MacKenzie, P.D. Ray, and Y. Tsuji Role and regulation of ferritin H in rotenone-mediated mitochondrial oxidative stress Free Radic. Biol. Med. 44 2008 1762 1771
43. S.S. Mao, R. Hua, X.P. Zhao, X. Qin, Z.Q. Sun, Y. Zhang, Y.Q. Wu, M.X. Jia, J.L. Cao, and Y.M. Zhang Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-kappaB pathway J. Neurotrauma 29 2012 1941 1959
44. R.P. Mason, R.F. Jacob, R. Kubant, A. Ciszewski, J.J. Corbalan, and T. Malinski Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats J. Cardiovasc. Pharmacol. 60 2012 467 473
45. R. Medeiros, R.D. Prediger, G.F. Passos, P. Pandolfo, F.S. Duarte, J.L. Franco, A.L. Dafre, G.G. Di, C.P. Figueiredo, R.N. Takahashi, M.M. Campos, and J.B. Calixto Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein J. Neurosci. 27 2007 5394 5404
46. I. Merchenthaler, M. Lane, and P. Shughrue Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system J. Comp. Neurol. 403 1999 261 280
47. R.B. Mounsey, and P. Teismann Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection Park. Dis. 2011 2010 617472
48. T. Numakawa, T. Matsumoto, Y. Numakawa, M. Richards, S. Yamawaki, and H. Kunugi Protective action of neurotrophic factors and estrogen against oxidative stress-mediated neurodegeneration J. Toxicol. 2011 2011 405194
49. S. Numazawa, M. Ishikawa, A. Yoshida, S. Tanaka, and T. Yoshida Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress Am. J. Physiol. Cell Physiol. 285 2003 C334 C342
50. C. Nunes, R.M. Barbosa, L. Almeida, and J. Laranjinha Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis Mol. Cell. Neurosci. 48 2011 94 103
51. S. Papa, and R.D. De Complex I deficiencies in neurological disorders Trends Mol. Med. 19 2013 61 69
52. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 2007 Academic Press New York
53. T. Perry, and N.H. Greig Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease Curr. Alzheimer Res. 2 2005 377 385
54. U. Pugazhenthi, K. Velmurugan, A. Tran, G. Mahaffey, and S. Pugazhenthi Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients Diabetologia 53 2010 2357 2368
55. M. Reale, M. Pesce, M. Priyadarshini, M.A. Kamal, and A. Patruno Mitochondria as an easy target to oxidative stress events in Parkinson's disease CNS Neurol. Disord. Drug Targets 11 2012 430 438
56. N. Satoh-Asahara, Y. Sasaki, H. Wada, M. Tochiya, A. Iguchi, R. Nakagawachi, S. Odori, S. Kono, K. Hasegawa, and A. Shimatsu A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients Metabolism 62 2013 347 351
57. A.H. Schapira, and C.W. Olanow Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 291 2004 358 364
58. A. Sedo, and R. Malik Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim. Biophys. Acta 1550 2001 107 116
59. R.P. Shannon DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes 62 2013 1029 1031
60. S. Takai, M. Yamada, T. Araki, H. Koshimizu, H. Nawa, and H. Hatanaka Shp-2 positively regulates brain-derived neurotrophic factor-promoted survival of cultured ventral mesencephalic dopaminergic neurons through a brain immunoglobulin-like molecule with tyrosine-based activation motifs/Shp substrate-1 J. Neurochem. 82 2002 353 364
61. P. Teismann, K. Tieu, O. Cohen, D.K. Choi, D.C. Wu, D. Marks, M. Vila, V. Jackson-Lewis, and S. Przedborski Pathogenic role of glial cells in Parkinson's disease Mov. Disord. 18 2003 121 129
62. V.N. Uversky Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration Cell. Tissue Res. 318 2004 225 241
63. T. Varga, A. Somogyi, G. Barna, B. Wichmann, G. Nagy, K. Racz, L. Selmeci, and G. Firneisz Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes Pathol. Oncol. Res. 17 2011 925 930
64. K. Velmurugan, R. Bouchard, G. Mahaffey, and S. Pugazhenthi Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells J. Neurochem. 123 2012 919 931
65. M. Vila, V. Jackson-Lewis, C. Guegan, D.C. Wu, P. Teismann, D.K. Choi, K. Tieu, and S. Przedborski The role of glial cells in Parkinson's disease Curr. Opin. Neurol. 14 2001 483 489
66. J. Wang, L. Qiao, S. Li, and G. Yang Protective effect of ginsenoside Rb1 against lung injury induced by intestinal ischemia-reperfusion in rats Molecules 18 2013 1214 1226
67. S.J. Weiss Oxygen, ischemia and inflammation Acta Physiol. Scand. Suppl. 548 1986 9 37
68. H. Wilms, L. Zecca, P. Rosenstiel, J. Sievers, G. Deuschl, and R. Lucius Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications Curr. Pharm. Des. 13 2007 1925 1928
69. J. Yang, X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, J. Cai, T.I. Peng, D.P. Jones, and X. Wang Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked Science 275 1997 1129 1132
70. W. Zhou, A. Liesz, H. Bauer, C. Sommer, B. Lahrmann, N. Valous, N. Grabe, and R. Veltkamp Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models Brain Pathol. 23 2013 34 44